SCHEMBL22868035

SCHEMBL22868035

COc1ccc2oc3cnccc3c(=O)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.71
RAB9A P51151 4/20 0.71
KDM4E B2RXH2 4/20 0.71
ALDH1A1 P00352 4/20 0.71
HPGD P15428 4/20 0.71
MAPT P10636 3/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
CASP3 P42574 1/20 0.71
SENP8 Q96LD8 1/20 0.71
SENP7 Q9BQF6 1/20 0.71
SENP6 Q9GZR1 1/20 0.71
MAOA P21397 2/20 0.67
RAD52 P43351 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 3/20 0.49
ABCB1 P08183 1/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619913 0.84 ALDH1A1 (1.00) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2161251 0.84 ALDH1A1 (1.00) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL7331388 0.82 KDM4E (0.86) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL394209 0.80 MAOA (1.00) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL1992749 0.80 KDM4E (0.58) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2000126 0.79 KDM4E (0.69) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL17819836 0.79 CSNK2A1 (0.50) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2372062 0.78 KDM4E (0.68) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL30593476 0.78 KMT2A (0.55) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL28458382 0.78 KMT2A (0.55) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3994125-B1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-12-24 EP disclosed
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-09-12 US disclosed
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-03-30 US disclosed
EP-3994125-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF Regeneron Pharmaceuticals, Inc. (US) 2022-05-11 EP disclosed
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 NPC1 404/4885RAB9A 3998/4885KDM4E 3109/4885
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 NPC1 404/4885RAB9A 3998/4885KDM4E 3109/4885
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof HSD17B3, HSD17B11, HSD17B1 NPC1 404/4885RAB9A 3998/4885KDM4E 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.